source
- Bristol Myers unveils data for one of its next-gen blood cancer drugsCalled mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.BioPharma Dive · 2mo ago↗ source
- STAT+: Trump administration seeks to overhaul federal grantmaking process, alarming researchersThe Trump administration has released a sweeping proposal to overhaul the bedrock regulation for all federal grants.STAT · 2mo ago↗ source
- Next FDA user fee deal is under review at the White HouseThe White House is examining a deal recently reached by the FDA and the biopharma industry that sets the prescription drug user fees that the sector will pay the agency from 2028 through 2032, sour…Endpoints